ViewsML is building the world's first virtual biomarker library using AI to generate per-cell spatial insights from routine pathology images without the need for physical immunohistochemistry (IHC). By virtualizing IHC, a diagnostic process that has remained unchanged for decades, ViewsML enables scientists and clinicians to generate biomarker staining results in minutes rather than the days to weeks required by conventional methods. 
The company’s platform analyzes standard H&E pathology slides to predict biomarker spatial expression at the individual cell level while preserving precious tissue samples and integrating into existing workflows. The result is faster biomarker discovery, accelerated clinical trials, and earlier insights that can guide treatment decisions for patients.
Working with leading pharmaceutical companies, diagnostic labs, and healthcare systems, ViewsML is helping unlock the full biological value of existing pathology data and enabling a faster, more scalable path to precision medicine. To learn more, visit www.viewsml.com.

ViewsML

Kenneth To

This department focuses on guiding the scientific direction and strategy of the organization.

Scientific Affairs

This department focuses on the design, implementation, and management of advanced technological systems and methodologies.

ViewsML

Org chart

Teams

Scientific Affairs

Technology Development

Offices

ViewsML

Org chart

Teams

Scientific Affairs

Technology Development

Offices

Related companies